Oversight for clinical uses of autologous adult stem cells: lessons from international regulations

Lysaght, T; Kerridge, I; Sipp, D; Porter, G; Capps, BJ

Access status:

Open Access

Field	Value	Language
dc.contributor.author	Lysaght, T
dc.contributor.author	Kerridge, I
dc.contributor.author	Sipp, D
dc.contributor.author	Porter, G
dc.contributor.author	Capps, BJ
dc.date.accessioned	2016-05-16
dc.date.available	2016-05-16
dc.date.issued	2013-01-01
dc.identifier.citation	Lysaght T, Kerridge I, Sipp D, Porter G, Capps BJ. Oversight for clinical use of autologous adult stem cells: lessons from international regulations. Cell Stem Cell. 2013;13(6):647-51.	en
dc.identifier.uri	http://hdl.handle.net/2123/14921
dc.description.abstract	Autologous adult stem cells (ASCs) are being administered by physicians for indications that have not been demonstrated as safe and effective in formal clinical trials. Examination of regulatory frameworks across five countries suggests that balancing the demands of research with clinical freedom has created structural weaknesses that are being exploited.	en
dc.description.sponsorship	funded by the Ministry of Education, Singapore, and the Humanities and Social Sciences (HSS) Division of the Office of the Deputy President (Research and Technology) at the National University of Singapore (NUS).	en
dc.language.iso	en	en
dc.publisher	Elsevier	en
dc.rights	Other
dc.subject	Autologous adult stem cells (ASCs)	en
dc.subject	stem cells	en
dc.subject	regulatory frameworks	en
dc.subject	clinical freedom	en
dc.title	Oversight for clinical uses of autologous adult stem cells: lessons from international regulations	en
dc.type	Article	en
usyd.faculty	Faculty of Medicine and Health, Sydney Health Ethics